Agency Information Collection Activities: Submission for OMB Review; Comment Request, 26114-26116 [2017-11632]
Download as PDF
mstockstill on DSK30JT082PROD with NOTICES
26114
Federal Register / Vol. 82, No. 107 / Tuesday, June 6, 2017 / Notices
Contact Person: Tatiana V. Cohen, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive Room 5213,
Bethesda, MD 20892, 301–455–2364,
tatiana.cohen@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Infectious,
Reproductive, Asthma and Pulmonary
Conditions: Additional Applications.
Date: June 28, 2017.
Time: 8:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Wyndham Grand Chicago
Riverfront, 71 East Wacker Drive, Chicago, IL
60601.
Contact Person: Suzanne Ryan, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3139,
MSC 7770, Bethesda, MD 20892, (301) 435–
1712, ryansj@csr.nih.gov.
Name of Committee: Population Sciences
and Epidemiology Integrated Review Group;
Infectious Diseases, Reproductive Health,
Asthma and Pulmonary Conditions Study
Section.
Date: June 28–29, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Wyndham Grand Chicago
Riverfront, 71 East Wacker Drive, Chicago, IL
60601.
Contact Person: Lisa Steele, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3139,
MSC 7770, Bethesda, MD 20892, (301) 257–
2638, steeleln@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR–16–
407: Emerging Epidemic Virus Research
Training.
Date: June 28, 2017.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Kenneth M. Izumi, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3204,
MSC 7808, Bethesda, MD 20892, 301–496–
6980, izumikm@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Fellowship:
Surgical Sciences Biomedical Imaging and
Bioengineering.
Date: June 28, 2017.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Donald Scott Wright,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5108,
MSC 7854, Bethesda, MD 20892, (301) 435–
8363, wrightds@csr.nih.gov.
VerDate Sep<11>2014
20:52 Jun 05, 2017
Jkt 241001
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Physiology and Pathobiology of
Musculoskeletal, Oral and Skin Systems.
Date: June 28, 2017.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Anshumali Chaudhari,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4124,
MSC 7802, Bethesda, MD 20892, (301) 435–
1210, chaudhaa@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Musculoskeletal Rehabilitations
Sciences.
Date: June 28, 2017.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Maria Nurminskaya, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, Bethesda, MD 20892, (301) 435–1222,
nurminskayam@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
Systems Science and Health in the
Behavioral and Social Science.
Date: June 28, 2017.
Time: 1:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Ping Wu, Ph.D., Scientific
Review Officer, HDM IRG, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3166,
Bethesda, MD 20892, 301–451–8428, wup4@
csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR17–029:
Dynamic Interactions between Systemic or
Non-Neuronal Systems and the Brain in
Aging and in Alzheimer’s Disease.
Date: June 28, 2017.
Time: 1:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Inese Z. Beitins, MD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6152,
MSC 7892, Bethesda, MD 20892, 301–435–
1034, beitinsi@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Neuronal and Glia Function in
Neurological Disorders.
Date: June 28, 2017.
Time: 1:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Deborah L. Lewis, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4183,
MSC 7850, Bethesda, MD 20892, 301–408–
9129, lewisdeb@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Toxicology.
Date: June 28, 2017.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Jonathan K. Ivins, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4040A,
MSC 7806, Bethesda, MD 20892, (301) 594–
1245, ivinsj@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA Panel:
Interdisciplinary Research to Understand the
Complex Biology of Resilience to
Alzheimer’s Disease Risk (R01).
Date: June 28, 2017.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Jonathan Arias, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5170,
MSC 7840, Bethesda, MD 20892, 301–435–
2406, ariasj@csr.nih.gov.
(Catalogue of Federal Domestic
Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical
Research, 93.306, 93.333, 93.337,
93.393–93.396, 93.837–93.844, 93.846–
93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: May 31, 2017.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–11590 Filed 6–5–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
E:\FR\FM\06JNN1.SGM
06JNN1
26115
Federal Register / Vol. 82, No. 107 / Tuesday, June 6, 2017 / Notices
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–1243.
Project: Notification of Intent To Use
Schedule III, IV, or V Opioid Drugs for
the Maintenance and Detoxification
Treatment of Opiate Addiction by a
‘‘Qualifying Other Practitioner’’—(OMB
No. 0930–0369)—Revision
The Substance Abuse and Mental
Health Services Administration
(SAMHSA) is requesting a revision from
the Office of Management and Budget
(OMB) for approval of the Notification
of Intent to Use Schedule III, IV, or V
Opioid Drugs for the Maintenance and
Detoxification Treatment of Opiate
Addiction by a ‘‘Qualifying Other
Practitioner.’’ The Notification of Intent
would allow SAMHSA to determine
whether other practitioners are eligible
to prescribe certain approved narcotic
treatment medications for the
maintenance or detoxification treatment
of opioid addiction.
This Notification of Intent is a result
of the Comprehensive Addiction and
Recovery Act (Pub. L. 114–198), which
was signed into law on July 22, 2016.
The law establishes criteria for nurse
practitioners (NPs) and physician
assistants (PAs) to qualify for a waiver
to prescribe covered medications. To be
eligible for a waiver, the NP or PA must:
Be licensed under State law to prescribe
schedule III, IV, or V medications for the
treatment of pain; fulfill qualification
requirements in the law for training and
experience; and fulfill qualification
requirements in the law for appropriate
supervision by a qualifying physician.
SAMHSA has the responsibility to
receive, review, approve, or deny waiver
requests.
Practitioners who meet the statutory
requirements will be eligible to
prescribe only those opioid treatment
medications that are controlled in
Schedules III, IV, or V, under the
Controlled Substance Act (CSA), that
are specifically approved by the Food
and Drug Administration (FDA) for the
treatment of opioid addiction, and are
not the subject of an ‘‘adverse
determination.’’ The only medications
that currently fulfill these requirements
are ones that contain the active
ingredient buprenorphine.
Below are the following changes:
NOI. The term ‘‘qualifying physician’’ is
specifically defined under 21 U.S.C.
823(g)(2)(G)(ii).
Address of Practice Location (NOI Item
2 and Instructions Section)
The newly revised instructions in
Section 2 now acknowledge that
practitioners may practice at multiple
practice locations, but may only list a
practice location address that matches
their DEA registration practice site.
Furthermore, the revised section
provides a link where practitioners may
add additional practice sites.
Certification of Qualifying Criteria (NOI
Item 8)
Use of Term of ‘‘Other Qualifying
Practitioners’’ (See NOI Items 1, 2, 6,
and 11)
The Statute section 823(g)(2)(B)(i)
refers to both physicians and mid-level
providers as ‘‘qualifying practitioners.’’
Therefore in order to avoid confusion
and redundancy the revised NOI
Instructions Section refers to ‘‘other
qualifying practitioners,’’ simply as
‘‘practitioners.’’
Use of Term of ‘‘Supervisory Physician
or Collaborative Physician’’ (NOI Item 8)
The third and fourth criteria in this
section created confusion regarding the
relationship with a qualifying physician
since providers are required to be
supervised by OR work with a
collaborative physician, but not both.
Therefore, the word ‘‘and’’ was replaced
by ‘‘or’’.
Patient Limits (Item 6: Purpose of
Notification)
Language was added allowing
practitioners who have treated 30
patients for at least one year to increase
their patient limit to 100. This second
notification to treat 100 patients was
omitted in the original NOI form.
Use of Term of ‘‘Qualifying Physician’’
(NOI Item 8)
The Controlled Substance Act (CSA)
requires that NPs and PAs be supervised
(or collaborate with) a ‘‘qualifying
physician’’ when required by state law
to work with a supervising physician
(see 21 U.S.C. 823(g)(2)(G)(iv)(III)).
SAMHSA added a footnote with a
definition of the term ‘‘qualifying
physician’’ means in the context of the
Number of
respondents
mstockstill on DSK30JT082PROD with NOTICES
Purpose of submission
Notification of Intent for Qualifying Other Practitioner to Use Schedule III,
IV, or V Opioid Drugs for the Maintenance and Detoxification Treatment
of Opiate Addiction by a ‘‘Qualifying Other Practitioner’’ under 21 U.S.C.
823(g)(2)—Nurse Practitioners ....................................................................
VerDate Sep<11>2014
20:52 Jun 05, 2017
Jkt 241001
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
The law specifically authorizes NPs
and PAs as eligible to apply to be a
‘‘Qualifying Other Practitioner.’’
However, the proposed Notification of
Intent form asks applicants to certify
that they are either an ‘‘advanced
practice nurse or physician assistant.’’
This difference in terminology was
considered confusing to potential
applicants. SAMHSA revised the first
attestation in Certification of Qualifying
Criteria to read ‘‘I certify that I am either
a nurse practitioner or physician
assistant who satisfies the definition of
a ‘qualifying other practitioner.’’
Identification of Training Providers
(NOI Item 8)
The previous NOI required that the
practitioner to write-in the name of
training provider(s)’ name(s). The
revised NOI allows practitioners to
select all applicable training providers
from a drop down list.
Certification of Capacity (NOI Item 9)
The second attestation in this section
was missing a verb. SAMHSA corrected
this error to reflect the statutory
language requiring qualifying
practitioners to attest to the capacity to
provide directly or by referral.
Certification of Maximum Patient Load
(NOI Item 10)
It was clarified that the second option
regarding increasing patient load to 100
refers to a second notifications (as
specified in the analogous NOI form for
physicians).
Privacy Act Information
This section noted that medical
specialty societies be used to verify
practitioner credentials. The revised
NOI replaced the words ‘‘medical
specialty societies’’ with ‘‘relevant
licensing boards to verify practitioners’
qualifications.’’
The following table is the estimated
hour burden:
Responses/
respondent
816
E:\FR\FM\06JNN1.SGM
Burden hours
1
06JNN1
.066
Total burden
hours
54
26116
Federal Register / Vol. 82, No. 107 / Tuesday, June 6, 2017 / Notices
Number of
respondents
Purpose of submission
Responses/
respondent
Burden hours
Total burden
hours
Notification of Intent for Qualifying Other Practitioner to Use Schedule III,
IV, or V Opioid Drugs for the Maintenance and Detoxification Treatment
of Opiate Addiction by a ‘‘Qualifying Other Practitioner’’ under 21 U.S.C.
823(g)(2)—Physician Assistants ..................................................................
590
1
.066
39
Total ..........................................................................................................
1,406
........................
........................
93
Written comments and
recommendations concerning the
proposed information collection should
be sent by July 6, 2017 to the SAMHSA
Desk Officer at the Office of Information
and Regulatory Affairs, Office of
Management and Budget (OMB). To
ensure timely receipt of comments, and
to avoid potential delays in OMB’s
receipt and processing of mail sent
through the U.S. Postal Service,
commenters are encouraged to submit
their comments to OMB via email to:
OIRA_Submission@omb.eop.gov.
Although commenters are encouraged to
send their comments via email,
commenters may also fax their
comments to: 202–395–7285.
Commenters may also mail them to:
Office of Management and Budget,
Office of Information and Regulatory
Affairs, New Executive Office Building,
Room 10102, Washington, DC 20503.
Summer King,
Statistician.
[FR Doc. 2017–11632 Filed 6–5–17; 8:45 am]
BILLING CODE 4162–20–P
I. Background and Authority
DEPARTMENT OF HOUSING AND
URBAN DEVELOPMENT
[Docket No. FR–5858–N–07]
Solicitation of Appointment
Nominations to the Housing
Counseling Federal Advisory
Committee
Office of the Assistant
Secretary for Housing—Federal Housing
Commissioner, Department of Housing
and Urban Development (HUD).
ACTION: Notice of Solicitation of
Appointment Nominations.
AGENCY:
The Department of Housing
and Urban Development (HUD)
established the Housing Counseling
Federal Advisory Committee (HCFAC)
on April 14, 2015. This notice invites
the public to nominate individuals to
fill one vacancy representing the real
estate industry for a three-year term.
DATES: Please submit nominations as
soon as possible, but no later than June
21, 2017.
mstockstill on DSK30JT082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
20:52 Jun 05, 2017
Jkt 241001
Nominations must be in
writing and submitted via email to
HCFAC.application@hud.gov.
Individuals that do not have internet
access may submit nominations to
Marjorie George, Housing Program
Technical Specialist, U.S. Department of
Housing and Urban Development, Office
of Housing Counseling, Office of
Outreach and Capacity Building, 200
Jefferson Avenue, Suite 300, Memphis,
TN 38103.
FOR FURTHER INFORMATION CONTACT:
Marjorie George, Housing Program
Technical Specialist, Office of Housing
Counseling, U.S. Department of Housing
and Urban Development, 200 Jefferson
Avenue, Suite 300, Memphis, TN 38103;
telephone number (901) 544–4228 (this
is not a toll-free number). Persons who
have difficulty hearing or speaking may
access this number via TTY by calling
the toll-free Federal Relay Service at
(800) 877–8339 (toll-free number).
Individuals with questions may also
email HCFAC.application@hud.gov and
in the subject line write ‘‘HCFAC
application question.’’
SUPPLEMENTARY INFORMATION:
ADDRESSES:
The Housing Counseling Federal
Advisory Committee (HCFAC) is
congressionally mandated to provide
advice to the Office of Housing
Counseling (OHC) (Pub. L. 111–203).
The HCFAC provides the OHC valuable
advice regarding its mission to provide
individuals and families with the
knowledge they need to obtain, sustain,
and improve their housing through a
strong national network of HUDapproved housing counseling agencies
and HUD-certified counselors. The
HCFAC, however, has no role in
reviewing or awarding of OHC housing
counseling grants and procurement
contracts. The HCFAC is subject to the
requirements of the Federal Advisory
Committee Act (5 U.S.C. Appendix), 41
CFR parts 101–6 and 102–3, and
Presidential Memorandum ‘‘Final
Guidance on Appointments of Lobbyists
to Federal Boards and Commissions,’’
dated June 18, 2010, along with any
relevant guidance published in the
Federal Register or otherwise issued by
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
the Office of Management and Budget
(OMB).1
The HCFAC shall consist of not more
than 12 individuals appointed by the
Secretary. The membership will equally
represent the mortgage industry, real
estate industry, consumers, and HUDapproved housing counseling agencies.
Each member shall be appointed in his
or her individual capacity for a term of
3 years and may be reappointed at the
discretion of the Secretary. Of the 12
members first appointed to the HCFAC
in 2016, 4 were appointed for an initial
term of 1 year, 4 were appointed for a
term of 2 years, and 4 were appointed
for a term of 3 years. The initial 12
appointments were made by the
Secretary on June 1, 2016, and the oneyear appointees terms will expire on
May 31, 2017. This notice indicates the
Secretary’s decision to reappoint to new
three-year terms the original appointees
for consumer, mortgage, and housing
counseling and to solicit applications to
address a vacancy for real estate due to
a withdrawal from consideration.
III. Nominations for the Housing
Counseling Federal Advisory
Committee
HUD is seeking nominations for an
individual whose experience is
representative of the real estate industry
to fill one vacancy. Individuals may
nominate themselves. Nominees must
be U.S. citizens, and cannot be
employees of the U.S. Government. All
nominees will be serving in their
‘‘individual capacity’’ and not in a
‘‘representative capacity,’’ therefore, no
Federally-registered lobbyists may serve
on the HCFAC.2 Individual capacity, as
clarified by OMB, refers to individuals
who are appointed to committees to
1 See 76 FR 61756 (‘‘Final Guidance on
Appointments of Lobbyists to Federal Boards and
Commissions’’); and 79 FR 47482 (‘‘Revised
Guidance on Appointment of Lobbyists to Federal
Advisory Committees, Boards, and Commissions’’);
see also https://www.whitehouse.gov/the:pressoffice/presidential-memorandum-lobbyists-agencyboards-and-commissions (‘‘Lobbyist on Agency
Boards and Commissions’’).
2 See 79 FR 47482 (‘‘Revised Guidance on
Appointment of Lobbyists to Federal Advisory
Committees, Boards, and Commissions’’) (clarifying
that federally registered lobbyists may not serve on
advisory committee, board, or Commission in an
‘‘individual capacity.’’).
E:\FR\FM\06JNN1.SGM
06JNN1
Agencies
[Federal Register Volume 82, Number 107 (Tuesday, June 6, 2017)]
[Notices]
[Pages 26114-26116]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-11632]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Agency Information Collection Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and Mental Health Services
Administration (SAMHSA) will publish a summary of information
collection requests under OMB review, in compliance with the
[[Page 26115]]
Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of
these documents, call the SAMHSA Reports Clearance Officer on (240)
276-1243.
Project: Notification of Intent To Use Schedule III, IV, or V Opioid
Drugs for the Maintenance and Detoxification Treatment of Opiate
Addiction by a ``Qualifying Other Practitioner''--(OMB No. 0930-0369)--
Revision
The Substance Abuse and Mental Health Services Administration
(SAMHSA) is requesting a revision from the Office of Management and
Budget (OMB) for approval of the Notification of Intent to Use Schedule
III, IV, or V Opioid Drugs for the Maintenance and Detoxification
Treatment of Opiate Addiction by a ``Qualifying Other Practitioner.''
The Notification of Intent would allow SAMHSA to determine whether
other practitioners are eligible to prescribe certain approved narcotic
treatment medications for the maintenance or detoxification treatment
of opioid addiction.
This Notification of Intent is a result of the Comprehensive
Addiction and Recovery Act (Pub. L. 114-198), which was signed into law
on July 22, 2016. The law establishes criteria for nurse practitioners
(NPs) and physician assistants (PAs) to qualify for a waiver to
prescribe covered medications. To be eligible for a waiver, the NP or
PA must: Be licensed under State law to prescribe schedule III, IV, or
V medications for the treatment of pain; fulfill qualification
requirements in the law for training and experience; and fulfill
qualification requirements in the law for appropriate supervision by a
qualifying physician. SAMHSA has the responsibility to receive, review,
approve, or deny waiver requests.
Practitioners who meet the statutory requirements will be eligible
to prescribe only those opioid treatment medications that are
controlled in Schedules III, IV, or V, under the Controlled Substance
Act (CSA), that are specifically approved by the Food and Drug
Administration (FDA) for the treatment of opioid addiction, and are not
the subject of an ``adverse determination.'' The only medications that
currently fulfill these requirements are ones that contain the active
ingredient buprenorphine.
Below are the following changes:
Address of Practice Location (NOI Item 2 and Instructions Section)
The newly revised instructions in Section 2 now acknowledge that
practitioners may practice at multiple practice locations, but may only
list a practice location address that matches their DEA registration
practice site. Furthermore, the revised section provides a link where
practitioners may add additional practice sites.
Use of Term of ``Other Qualifying Practitioners'' (See NOI Items 1, 2,
6, and 11)
The Statute section 823(g)(2)(B)(i) refers to both physicians and
mid-level providers as ``qualifying practitioners.'' Therefore in order
to avoid confusion and redundancy the revised NOI Instructions Section
refers to ``other qualifying practitioners,'' simply as
``practitioners.''
Use of Term of ``Supervisory Physician or Collaborative Physician''
(NOI Item 8)
The third and fourth criteria in this section created confusion
regarding the relationship with a qualifying physician since providers
are required to be supervised by OR work with a collaborative
physician, but not both. Therefore, the word ``and'' was replaced by
``or''.
Patient Limits (Item 6: Purpose of Notification)
Language was added allowing practitioners who have treated 30
patients for at least one year to increase their patient limit to 100.
This second notification to treat 100 patients was omitted in the
original NOI form.
Use of Term of ``Qualifying Physician'' (NOI Item 8)
The Controlled Substance Act (CSA) requires that NPs and PAs be
supervised (or collaborate with) a ``qualifying physician'' when
required by state law to work with a supervising physician (see 21
U.S.C. 823(g)(2)(G)(iv)(III)). SAMHSA added a footnote with a
definition of the term ``qualifying physician'' means in the context of
the NOI. The term ``qualifying physician'' is specifically defined
under 21 U.S.C. 823(g)(2)(G)(ii).
Certification of Qualifying Criteria (NOI Item 8)
The law specifically authorizes NPs and PAs as eligible to apply to
be a ``Qualifying Other Practitioner.'' However, the proposed
Notification of Intent form asks applicants to certify that they are
either an ``advanced practice nurse or physician assistant.'' This
difference in terminology was considered confusing to potential
applicants. SAMHSA revised the first attestation in Certification of
Qualifying Criteria to read ``I certify that I am either a nurse
practitioner or physician assistant who satisfies the definition of a
`qualifying other practitioner.''
Identification of Training Providers (NOI Item 8)
The previous NOI required that the practitioner to write-in the
name of training provider(s)' name(s). The revised NOI allows
practitioners to select all applicable training providers from a drop
down list.
Certification of Capacity (NOI Item 9)
The second attestation in this section was missing a verb. SAMHSA
corrected this error to reflect the statutory language requiring
qualifying practitioners to attest to the capacity to provide directly
or by referral.
Certification of Maximum Patient Load (NOI Item 10)
It was clarified that the second option regarding increasing
patient load to 100 refers to a second notifications (as specified in
the analogous NOI form for physicians).
Privacy Act Information
This section noted that medical specialty societies be used to
verify practitioner credentials. The revised NOI replaced the words
``medical specialty societies'' with ``relevant licensing boards to
verify practitioners' qualifications.''
The following table is the estimated hour burden:
----------------------------------------------------------------------------------------------------------------
Number of Responses/ Total burden
Purpose of submission respondents respondent Burden hours hours
----------------------------------------------------------------------------------------------------------------
Notification of Intent for Qualifying Other 816 1 .066 54
Practitioner to Use Schedule III, IV, or V
Opioid Drugs for the Maintenance and
Detoxification Treatment of Opiate Addiction by
a ``Qualifying Other Practitioner'' under 21
U.S.C. 823(g)(2)--Nurse Practitioners..........
[[Page 26116]]
Notification of Intent for Qualifying Other 590 1 .066 39
Practitioner to Use Schedule III, IV, or V
Opioid Drugs for the Maintenance and
Detoxification Treatment of Opiate Addiction by
a ``Qualifying Other Practitioner'' under 21
U.S.C. 823(g)(2)--Physician Assistants.........
---------------------------------------------------------------
Total....................................... 1,406 .............. .............. 93
----------------------------------------------------------------------------------------------------------------
Written comments and recommendations concerning the proposed
information collection should be sent by July 6, 2017 to the SAMHSA
Desk Officer at the Office of Information and Regulatory Affairs,
Office of Management and Budget (OMB). To ensure timely receipt of
comments, and to avoid potential delays in OMB's receipt and processing
of mail sent through the U.S. Postal Service, commenters are encouraged
to submit their comments to OMB via email to:
OIRA_Submission@omb.eop.gov. Although commenters are encouraged to send
their comments via email, commenters may also fax their comments to:
202-395-7285. Commenters may also mail them to: Office of Management
and Budget, Office of Information and Regulatory Affairs, New Executive
Office Building, Room 10102, Washington, DC 20503.
Summer King,
Statistician.
[FR Doc. 2017-11632 Filed 6-5-17; 8:45 am]
BILLING CODE 4162-20-P